Samsung Biologics inks $518M production contract with US pharma, extending CDMO's dealmaking streak
Samsung Biologics, which has enjoyed a booming contract drug manufacturing streak over the past year, has inked another deal, this one worth 737.3 billion Korean won ($518 million).
Samsung Biologics, which has enjoyed a booming contract drug manufacturing streak over the past year, has inked another deal, this one worth 737.3 billion Korean won ($518 million).
